UNSPSC 51412403: Visnadine

This classification denotes a vasodilating agent with the molecular formula C21H24O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0RL4V0K263, chemically known as 3,4,5-trihydroxy-2,2-dimethyl-6-chromanacrylic acid delta-lactone 4-acetate 3-(2-methylbutyrate) but generally known as visnadine, which bears US NIH Compound Identifier 10157. European Medicines Agency schedules Visnadine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00083MIG.

UNSPSC 51412403 Visnadine, a Commodity code, covers pharmaceutical active ingredients and formulated medications that state and local governments procure for emergency medical services, public health programs, and institutional healthcare settings. Recent solicitations show state and local buyers acquiring specific advanced life support medications—epinephrine, adenosine, labetalol, and diltiazem—in bulk quantities for fire rescue and emergency response, as well as generic multi-source pharmaceuticals and over-the-counter products distributed through state health and human services channels and cooperative purchasing alliances. The City of Tampa's fire rescue system and state health agencies are the primary issuing bodies visible in current activity, with participation from regional cooperative purchasing vehicles serving multiple jurisdictions.

Activity spans Florida, Texas, and Minnesota, with the most recent opportunities posted between January and April 2026. The City of Tampa issued an IFB (Solicitation 26P00188) on April 24, 2026, for advanced life support medications with a response deadline of April 8, 2026, and an estimated contract value of $40,000.00; the contract includes a 5 percent bid discount for Small Local Business Enterprise participation and requires nine-month minimum shelf life and ten-day delivery. The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), issued an RFP (S1070000015802) with a response deadline of March 26, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products effective July 1, 2026, with award decisions weighted 75 percent on price competitiveness and 25 percent on administrative compliance and pricing format flexibility. The Texas Health and Human Services Commission issued an RFI (HHS0017013) on April 3, 2026, as an exploratory phase to gather vendor capabilities for a direct-to-manufacturer prescription program, signaling potential future procurement activity beyond current formalized solicitations.